Genomics is a massive opportunity. It is also easy to misread.
Genomics, precision medicine, AI biology and synthetic biology are moving from research into clinics, products, platforms, infrastructure and global markets. The market is already large, and still growing fast: one estimate puts the genomics market at $47.1bn in 2025, growing to $85.1bn by 2030 (MarketsandMarkets); precision medicine, synthetic biology and AI drug discovery are also projected to grow rapidly over the next decade. The upside is real: better diagnosis, better treatment, better food systems, better materials, better biodiversity monitoring and better biological infrastructure. But biology is not software, and investors who apply pure digital logic to living systems can miss the real risks.
Because in genomics, the expensive mistake is often not missing the market; it is misunderstanding the biology.
What investors are underestimating
I have done technical due diligence for venture investment, helped with seed funding, and spoken with many VCs, business angels, founders and biotech teams. The biggest issue I see is not lack of excitement; it is poor translation between digital investment logic and biological reality. In digital markets, speed, scale and iteration can solve many problems. In genomics and biotech, the hard questions are often physical, clinical, regulatory and biological: does it work in real samples, across patients, at scale, under quality controls, with a buyer, a reimbursement path and a credible route to implementation?
The biggest traps I see
Too much money chasing weak novelty
I have seen capital chase ventures where the deck is strong, the language is fashionable, and the actual product is not very novel. AI plus genomics plus precision medicine is not automatically a company, and “platform” is not a moat unless it creates repeatable value, defensible data, useful products and a credible route to market.
Confusing a research result with a product
A result can be exciting and still be years away from being useful. Research success is not the same as clinical evidence, regulatory clearance, manufacturing quality, reimbursement, adoption or safe real-world deployment, and many promising technologies will need long runways before they can become reliable certified products.
Underestimating delivery
In many biology companies, delivery is not a technical detail; it is the company. If the product depends on getting biological material to the right place, intact, safe, consistent and effective, that risk needs to be understood before too much capital is committed.
Missing the buyer
Some companies have something that works and genuinely helps people, but there may be no established market channel, no reimbursement pathway, no obvious buyer, and no customer awareness that the product is even possible. A useful product can still fail if nobody knows how to buy it.
Funding companies before they know what they are
I see startups several years in, with significant headcount, still searching for their USP, business model or real customer. In genomics, that is expensive: the burn can grow long before the company has proved what it actually is.
What I can help investors test
I can help investors test whether the science is plausible, the product is genuinely novel, the evidence is strong enough for the stage, the platform is defensible, the market is real, the buyer is identifiable, the regulatory pathway is credible, and the implementation risks are understood. I can also help identify what is still assumed, what competitors are already doing, what could kill the company after the round, and what would need to be true for the opportunity to become very valuable.
Useful for
VC funds, angel investors, family offices, deep-tech investors entering biology, biotech investors, investment committees, boards reviewing genomics or AI-biology opportunities, and founders preparing for diligence.
Support can include
Technical due diligence, scientific claim review, genomics and AI-biology platform assessment, product and roadmap review, competitor review, market-readiness assessment, implementation-risk assessment, investment committee questions, independent second opinions before investment decisions, and strategic briefings on where genomics is going.
Invest in companies that can survive contact with reality
The opportunity is enormous, and some of these companies will change medicine, food, biodiversity, climate resilience and human health. But this is also a field where weak science, vague platforms, poor delivery, unclear buyers and over-reaching claims can absorb a lot of capital. If you want help navigating genomics, AI biology, precision medicine or synthetic biology before investing, please get in touch.